Stigmatization of medications for opioid use disorder in 12-step support groups and participant responses

被引:37
作者
Andraka-Christou, Barbara [1 ,2 ]
Totaram, Rachel [1 ]
Randall-Kosich, Olivia [3 ]
机构
[1] Univ Cent Florida, Dept Hlth Management & Informat, 839 Jade Forest Ave, Orlando, FL 32828 USA
[2] Univ Cent Florida, Dept Internal Med, Orlando, FL 32816 USA
[3] Georgia State Univ, Sch Publ Hlth, Atlanta, GA 30303 USA
关键词
Methadone; buprenorphine; 12-step; medication-assisted treatment; stigma; support groups; medications for opioid use disorder; METHADONE-MAINTENANCE TREATMENT; SELF-HELP GROUPS; ASSISTED TREATMENT; SMART RECOVERY; ADDICTION RECOVERY; BUPRENORPHINE; ABUSE; DEPENDENCE; RETENTION; DIVERSION;
D O I
10.1080/08897077.2021.1944957
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Background: 12-step groups are the most common approach to managing opioid use disorder (OUD) in the U.S. Medications for OUD (MOUD) are the most effective tool for preventing opioid misuse and relapse. Previous research has identified stigma of MOUD in 12-step groups. Objectives: We sought to identify how MOUD stigma is operationalized in 12-step groups and to identify responses to stigma. Methods: We recruited individuals with both MOUD experience and 12-step group experience from three syringe exchange programs in the U.S. using snowball sampling. We conducted individual telephone semi-structured interviews during 2018 and 2019. We coded data in Dedoose software and conducted thematic analysis using iterative categorization. Results: We recruited 30 individuals meeting our inclusion criteria. The following stigma operationalization methods were identified: prohibiting people using MOUD from speaking at meetings; encouraging shortened duration of MOUD treatment; refusing to sponsor people using MOUD; and refusing to let people using MOUD claim recovery time. Responses to stigma included the following: feeling shame; feeling anger; shopping around for different groups, leaving the group, or forming a new group; not revealing MOUD utilization or only telling a sponsor; speaking out on behalf of MOUD; and using cognitive approaches to avoid stigma internalization. Cognitive approaches included believing that anti-MOUD stigma is contrary to 12-step principles; disregarding statements as inaccurate based on one's experience of MOUD benefits; and accepting that all groups of humans have some ignorant people. Conclusion: Healthcare systems should help address MOUD stigma experienced by patients in 12-step groups, such as by offering non-12-step alternative groups and encouraging MOUD healthcare providers to prepare patients for potential stigma they may face. Some stigma response options, like shopping around for different groups, may not be feasible in rural areas or for participants newer to recovery.
引用
收藏
页码:415 / 424
页数:10
相关论文
共 61 条
[41]   A longitudinal study of organizational formation, innovation adoption, and dissemination activities within the National Drug Abuse Treatment Clinical Trials Network [J].
Roman, Paul M. ;
Abraham, Amanda J. ;
Rothrauff, Tanja C. ;
Knudsen, Hannah K. .
JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2010, 38 (04) :S44-S52
[42]   Can a 12-Step Program Work in Methadone Maintenance Treatment? [J].
Ronel, Natti ;
Gueta, Keren ;
Abramsohn, Yali ;
Caspi, Nir ;
Adelson, Miriam .
INTERNATIONAL JOURNAL OF OFFENDER THERAPY AND COMPARATIVE CRIMINOLOGY, 2011, 55 (07) :1135-1153
[43]   Patterns of Buprenorphine-Naloxone Treatment for Opioid Use Disorder in a Multistate Population [J].
Saloner, Brendan ;
Daubresse, Matthew ;
Alexander, G. Caleb .
MEDICAL CARE, 2017, 55 (07) :669-676
[44]   Saturation in qualitative research: exploring its conceptualization and operationalization [J].
Saunders, Benjamin ;
Sim, Julius ;
Kingstone, Tom ;
Baker, Shula ;
Waterfield, Jackie ;
Bartlam, Bernadette ;
Burroughs, Heather ;
Jinks, Clare .
QUALITY & QUANTITY, 2018, 52 (04) :1893-1907
[45]   Clinician Beliefs and Attitudes about Buprenorphine/Naloxone Diversion [J].
Schuman-Olivier, Zev ;
Connery, Hilary ;
Griffin, Margaret L. ;
Wyatt, Steve A. ;
Wartenberg, Alan A. ;
Borodovsky, Jacob ;
Renner, John A., Jr. ;
Weiss, Roger D. .
AMERICAN JOURNAL ON ADDICTIONS, 2013, 22 (06) :574-580
[46]   Update on Barriers to Pharmacotherapy for Opioid Use Disorders [J].
Sharma, Anjalee ;
Kelly, Sharon M. ;
Mitchell, Shannon Gwin ;
Gryczynski, Jan ;
O'Grady, Kevin E. ;
Schwartz, Robert P. .
CURRENT PSYCHIATRY REPORTS, 2017, 19 (06)
[47]   Treatment Of Opioid Use Disorder Among Commercially Insured US Adults, 2008-17 [J].
Shen, Karen ;
Barrette, Eric ;
Dafny, Leemore S. .
HEALTH AFFAIRS, 2020, 39 (06) :993-1001
[48]   Retention in medication-assisted treatment for opiate dependence: A systematic review [J].
Timko, Christine ;
Schultz, Nicole R. ;
Cucciare, Michael A. ;
Vittorio, Lisa ;
Garrison-Diehn, Christina .
JOURNAL OF ADDICTIVE DISEASES, 2016, 35 (01) :22-35
[49]   Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups [J].
Tong, Allison ;
Sainsbury, Peter ;
Craig, Jonathan .
INTERNATIONAL JOURNAL FOR QUALITY IN HEALTH CARE, 2007, 19 (06) :349-357
[50]  
U.S. Public Health Service, 2018, Facing addiction in America: The surgeon general's spotlight on opioids